Register an account to search through 14,000+ stocks! 

Ad

VIF – Vifor Pharma AG

Ad

✔ COMPLIANT

★★★

Pharmaceuticals | Europe

Business: PASS

Vifor Pharma AG has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.

Financials: PASS

The financials pass all the three standards we check against.

FTSE

Debt/A11.51%
Cash/A19.48%
(AR+C)/A26.84%

AAOIFI

Debt/MC5.62%
Cash/MC0.01%

DJIM

Debt/24MC6.94%
Cash/24MC11.74%
AR/24MC4.43%

Total Analysts: 12

Recommendation Rating

3

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 165.3

Low: 12

High: 182.1

Market cap11442079101
Assets5590440693
Dividends per Share2.19
Revenue Growth-0.7

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company’s portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

✔ FTSE✔ AAOIFI✔ DJIM

✔ COMPLIANT

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

Ad

Responses